Banner Health Article Reignites Kratom Safety Debate, Underscores Urgent Need for Merchant Compliance

Banner Health Article Reignites Kratom Safety Debate, Underscores Urgent Need for Merchant Compliance

Phoenix, AZ – April 14, 2026 – A recent article from Banner Health, titled "Kratom is Legal, But Is It Really Safe?", has brought renewed attention to the ongoing debate surrounding the safety and regulation of kratom products. Published on April 13, 2026, the piece features insights from Bryan Kuhn, a pharmacist and poison education specialist with Banner Health, who highlights significant concerns regarding the plant-based substance.

The Banner Health article emphasizes that while kratom, derived from the Mitragyna speciosa tree, is legal in many U.S. states, it is not approved by the U.S. Food and Drug Administration (FDA) and products remain unregulated for consistency, purity, or safety. Kuhn notes that kratom contains active compounds like mitragynine, which can produce both stimulant and opioid-like effects depending on the dosage. A key concern raised is the presence of concentrated compounds, specifically 7-hydroxymitragynine (7-OH), which may elevate the risk of addiction and overdose. The article links kratom use to serious health risks, including addiction, overdose, seizures, hallucinations, liver injury, rapid heart rate, and confusion, largely due to the variability in product strength and ingredients.

Why This Matters to Kratom Merchants and Consumers

For consumers, this news brief serves as a critical warning from a reputable healthcare provider about the potential dangers of unregulated kratom. The lack of FDA oversight means consumers cannot be assured of product quality, purity, or accurate labeling, increasing the risk of adverse health outcomes. The article encourages individuals with concerns about substance use to contact healthcare providers or poison control, potentially leading to increased public scrutiny and caution around kratom products.

For kratom merchants, this publication underscores the growing pressure for increased transparency and robust compliance. The continuous public health warnings from organizations like Banner Health, coupled with rising poison center calls and hospitalizations linked to kratom, are direct signals that the industry's "high-risk" status is firmly entrenched. This environment necessitates a proactive approach to compliance to maintain consumer trust and operational viability in a rapidly evolving regulatory landscape.

Compliance Implications for the Kratom Industry

The Banner Health article, by highlighting the unregulated nature of kratom, implicitly calls for stricter compliance. This aligns with a broader trend of state-level legislative action, such as North Carolina's HB 468 and South Carolina's Act 35, which are setting new precedents for consumer protection by mandating comprehensive testing and specific alkaloid limits. Several states have enacted or are considering Kratom Consumer Protection Acts (KCPAs) to establish quality and safety standards. The FDA continues to issue warnings about kratom and particularly 7-OH, with some federal officials even recommending a nationwide ban on concentrated 7-OH products. California, for instance, has achieved significant compliance in removing illicit kratom and 7-OH products from store shelves.

What High-Risk Merchants Need to Know: COAs, Lab Testing, and Regulatory Compliance

High-risk kratom merchants face stringent requirements from payment processors and, increasingly, from state regulators. To navigate this environment successfully, adherence to the following is crucial:

• Certificates of Analysis (COAs): Merchants must provide third-party Certificates of Analysis for all kratom products. These COAs should be batch-specific, recent (typically within 6-12 months), and issued by ISO/IEC 17025-accredited laboratories. COAs are vital for verifying alkaloid content (mitragynine and 7-OH) and confirming the absence of harmful contaminants.
• Comprehensive Lab Testing: Beyond alkaloid potency, rigorous lab testing is essential for screening contaminants such as heavy metals (lead, arsenic, cadmium, mercury) and microbial pathogens (salmonella, E. coli, yeast, mold). States implementing KCPAs often set specific thresholds for these contaminants and for alkaloid concentrations (e.g., mitragynine between 0.5% and 2%, and 7-OH not exceeding 0.02% of total product weight).
• Regulatory Compliance & Labeling:
  • No Medical Claims: Products and marketing materials must avoid any claims that kratom can diagnose, treat, cure, or prevent any disease, as it is not FDA-approved for such uses.
  • Accurate Labeling: Labels should include a unique batch or lot number that matches the COA, suggested use, serving size, recommended daily intake, and the precise amounts of mitragynine and 7-hydroxymitragynine.
  • Responsible Marketing: Avoid marketing that appeals to minors, such as candy-like flavors or cartoon characters on packaging.
  • Documentation: Maintain meticulous records of all laboratory testing and product registrations, as required by state laws.

Failure to meet these compliance standards is a primary reason for merchant account terminations, frozen funds, and application denials in the high-risk payment processing sector. As public health entities like Banner Health continue to scrutinize kratom, proactive and robust compliance efforts are not just best practice—they are a necessity for survival in the kratom industry.